{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:44:35Z","timestamp":1785818675503,"version":"3.56.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nanoparticles enable sustained drug release. Infants with retinopathy of prematurity (ROP) treated with Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, develop systemic toxicity due to repeat dosing from a short half-life. We optimized fabrication of Bevacizumab nanoparticles in a mouse oxygen-induced retinopathy (OIR) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Bevacizumab nanoparticle fabrication was optimized for polymer type and ratio, solvent, drug loading capacity (DL) %, and encapsulation efficiency (EE) %. Nanoparticles were characterized using Scanning electron microscopy (SEM), Transmission electron microscopy (TEM), and Fourier-transform infrared spectroscopy (FTIR). C57BL6\/J mice exposed to OIR received intravitreal Empty (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918), Bevacizumab-loaded nanoparticles (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918), or Free Bevacizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) at P13 to right eyes. Fluorescein Angiography (FA) was performed at P20. Retinal avascular area, arterial tortuosity, and vein width were quantified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SEM showed spherical nanospheres. TEM and FTIR confirmed drugs within nanospheres. DL and EE were optimized at 2.3% and 80%. There was sustained drug release of 80% at 72\u2009h. FA showed increased retinal avascular area, reduced retinal artery tortuosity, and retinal vein width in Bevacizumab nanoparticle treated right eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravitreal administration of Bevacizumab-loaded nanoparticles significantly improved retinal vasculopathy in mice with OIR, without repeat dosing. Further toxicity studies are needed before clinical translation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Retinopathy of Prematurity is treated with anti-vascular endothelial growth factor drugs such as Bevacizumab.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Anti-VEGF drugs result in systemic toxicity from repeat dosing due to their short half-life.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We, for the first time, show the feasibility and optimization of nanoparticle formulation of bevacizumab in a mouse model of ROP.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Intravitreal Bevacizumab nanoparticles may prevent systemic toxicity and improve outcomes in infants with ROP.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-025-04508-w","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:03:31Z","timestamp":1761588211000},"page":"2367-2377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal Bevacizumab nanoparticles ameliorates retinal vasculopathy in an in vivo mouse model of retinopathy of prematurity"],"prefix":"10.1038","volume":"99","author":[{"given":"Suganesh","family":"Raghunathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfiya","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olachi J.","family":"Mezu-Ndubuisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"4508_CR1","doi-asserted-by":"crossref","unstructured":"Mezu-Ndubuisi, O. J. In vivo angiography quantifies oxygen-induced retinopathy vascular recovery. Optometry Vis. Sci. 93, 1268\u20131279 (2016).","DOI":"10.1097\/OPX.0000000000000941"},{"key":"4508_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41433-018-0205-1","volume":"33","author":"OJ Mezu-Ndubuisi","year":"2019","unstructured":"Mezu-Ndubuisi, O. J., Adams, T., Taylor, L. K., Nwaba, A. & Eickhoff, J. Simultaneous assessment of aberrant retinal vascularization, thickness, and function in an in vivo mouse oxygen-induced retinopathy model. Eye 33, 363\u2013373 (2019).","journal-title":"Eye"},{"key":"4508_CR3","first-page":"257","volume":"26","author":"OJ Mezu-Ndubuisi","year":"2020","unstructured":"Mezu-Ndubuisi, O. J. et al. Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy. Mol. Vis. 26, 257 (2020).","journal-title":"Mol. Vis."},{"key":"4508_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","volume":"74","author":"H Blencowe","year":"2013","unstructured":"Blencowe, H., Lawn, J. E., Vazquez, T., Fielder, A. & Gilbert, C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr. Res. 74, 35\u201349 (2013).","journal-title":"Pediatr. Res."},{"key":"4508_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert, C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum. Dev. 84, 77\u201382 (2008).","journal-title":"Early Hum. Dev."},{"key":"4508_CR6","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.4103\/IJO.IJO_2714_23","volume":"71","author":"CE Gilbert","year":"2023","unstructured":"Gilbert, C. E. Global perspectives of retinopathy of prematurity. Indian J. Ophthalmol. 71, 3431\u20133433 (2023).","journal-title":"Indian J. Ophthalmol."},{"key":"4508_CR7","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.ophtha.2020.01.034","volume":"127","author":"EA Palmer","year":"2020","unstructured":"Palmer, E. A. et al. Incidence and early course of retinopathy of prematurity. Ophthalmology 127, S84\u2013S96 (2020).","journal-title":"Ophthalmology"},{"key":"4508_CR8","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang, M. F. et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 128, e51\u2013e68 (2021).","journal-title":"Ophthalmology"},{"key":"4508_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","volume":"10","author":"J Chen","year":"2007","unstructured":"Chen, J. & Smith, L. E. Retinopathy of prematurity. Angiogenesis 10, 133\u2013140 (2007).","journal-title":"Angiogenesis"},{"key":"4508_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"M Tolentino","year":"2011","unstructured":"Tolentino, M. Systemic and ocular safety of intravitreal anti-vegf therapies for ocular neovascular disease. Surv. Ophthalmol. 56, 95\u2013113 (2011).","journal-title":"Surv. Ophthalmol."},{"key":"4508_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.semperi.2019.05.011","volume":"43","author":"DK VanderVeen","year":"2019","unstructured":"VanderVeen, D. K. & Cataltepe, S. U. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. Semin Perinatol. 43, 375\u2013380 (2019).","journal-title":"Semin Perinatol."},{"key":"4508_CR12","doi-asserted-by":"publisher","first-page":"305.e301","DOI":"10.1016\/j.jaapos.2022.08.524","volume":"26","author":"C Hoppe","year":"2022","unstructured":"Hoppe, C. et al. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity. J. AAPOS 26, 305.e301\u2013305.e306 (2022).","journal-title":"J. AAPOS"},{"key":"4508_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamaophthalmol.2022.3788","volume":"140","author":"CR Nitkin","year":"2022","unstructured":"Nitkin, C. R. et al. Pulmonary hypertension in preterm infants treated with laser vs anti-vascular endothelial growth factor therapy for retinopathy of prematurity. JAMA Ophthalmol. 140, 1085\u20131094 (2022).","journal-title":"JAMA Ophthalmol."},{"key":"4508_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S. & Singh, R. J. Pharmacokinetics of intravitreal Bevacizumab (Avastin). Ophthalmology 114, 855\u2013859 (2007).","journal-title":"Ophthalmology"},{"key":"4508_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","volume":"129","author":"SF Freedman","year":"2022","unstructured":"Freedman, S. F. et al. Low-and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes. Ophthalmology 129, 1120\u20131128 (2022).","journal-title":"Ophthalmology"},{"key":"4508_CR16","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh, R. et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 94, e417\u2013e420 (2016).","journal-title":"Acta Ophthalmol."},{"key":"4508_CR17","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL H\u00e5rd","year":"2011","unstructured":"H\u00e5rd, A. L. & Hellstr\u00f6m, A. On safety, pharmacokinetics and dosage of bevacizumab in rop treatment\u2013a review. Acta Paediatr. 100, 1523\u20131527 (2011).","journal-title":"Acta Paediatr."},{"key":"4508_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A. & Chuang, A. Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl. J. Med. 364, 603\u2013615 (2011).","journal-title":"N. Engl. J. Med."},{"key":"4508_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","volume":"38","author":"Y Yonekawa","year":"2018","unstructured":"Yonekawa, Y. et al. Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina 38, 1079\u20131083 (2018).","journal-title":"Retina"},{"key":"4508_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03959-4","volume":"7","author":"F Sousa","year":"2017","unstructured":"Sousa, F. et al. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci. Rep. 7, 3736 (2017).","journal-title":"Sci. Rep."},{"key":"4508_CR21","doi-asserted-by":"publisher","first-page":"105850","DOI":"10.1016\/j.jddst.2024.105850","volume":"98","author":"I Fatima","year":"2024","unstructured":"Fatima, I. et al. Advances in targeted nano-delivery of bevacizumab using nanoparticles: current insights, innovations, and future perspectives. J. Drug Deliv. Sci. Technol. 98, 105850 (2024).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"4508_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari, A., Yadav, S. K. & Yadav, S. C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces 75, 1\u201318 (2010).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"4508_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/02713683.2018.1542736","volume":"44","author":"OJ Mezu-Ndubuisi","year":"2019","unstructured":"Mezu-Ndubuisi, O. J. et al. Intravitreal delivery of Vegf-A165-loaded Plga microparticles reduces retinal Vaso-obliteration in an in vivo mouse model of retinopathy of prematurity. Curr. Eye Res. 44, 275\u2013286 (2019).","journal-title":"Curr. Eye Res."},{"key":"4508_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1874364101206010054","volume":"6","author":"F Li","year":"2012","unstructured":"Li, F., Hurley, B., Liu, Y., Leonard, B. & Griffith, M. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.  open Ophthalmol. J. 6, 54 (2012).","journal-title":"open Ophthalmol. J."},{"key":"4508_CR25","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1002\/pi.4972","volume":"64","author":"B Felice","year":"2015","unstructured":"Felice, B., Prabhakaran, M. P., Zamani, M., Rodr\u00edguez, A. P. & Ramakrishna, S. Electrosprayed Poly (Vinyl Alcohol) particles: preparation and evaluation of their drug release profile. Polym. Int. 64, 1722\u20131732 (2015).","journal-title":"Polym. Int."},{"key":"4508_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/21691401.2023.2207606","volume":"51","author":"A Saleh","year":"2023","unstructured":"Saleh, A. et al. Antiviral and antibacterial potential of electrosprayed Pva\/Plga nanoparticles loaded with chlorogenic acid for the management of coronavirus and pseudomonas aeruginosa lung infection. Artif. Cells Nanomed. Biotechnol. 51, 255\u2013267 (2023).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"4508_CR27","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.msec.2012.05.016","volume":"32","author":"D Pencheva","year":"2012","unstructured":"Pencheva, D., Bryaskova, R. & Kantardjiev, T. Polyvinyl Alcohol\/Silver Nanoparticles (Pva\/Agnps) as a model for testing the biological activity of hybrid materials with included silver nanoparticles. Mater. Sci. Eng. C 32, 2048\u20132051 (2012).","journal-title":"Mater. Sci. Eng. C"},{"key":"4508_CR28","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.jddst.2020.101907","volume":"60","author":"JC Ramirez","year":"2020","unstructured":"Ramirez, J. C. et al. Preparation of Pdlla and Plga nanoparticles stabilized with Pva and a Pva-Sds mixture: studies on particle size, degradation and drug release. J. Drug Deliv. Sci. Technol. 60, 101907 (2020).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"4508_CR29","first-page":"101","volume":"35","author":"L Smith","year":"1994","unstructured":"Smith, L. et al. Oxygen-induced retinopathy in the mouse. Investig. Ophthalmol. Vis. Sci. 35, 101\u2013111 (1994).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"4508_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1203\/PDR.0b013e3181973dc8","volume":"65","author":"S Vanhaesebrouck","year":"2009","unstructured":"Vanhaesebrouck, S. et al. Oxygen-induced retinopathy in mice: amplification by neonatal Igf-I deficit and attenuation by Igf-I administration. Pediatr. Res. 65, 307\u2013310 (2009).","journal-title":"Pediatr. Res."},{"key":"4508_CR31","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.2353\/ajpath.2010.100526","volume":"177","author":"A Stahl","year":"2010","unstructured":"Stahl, A. et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy.  Am. J. Pathol. 177, 2715\u20132723 (2010).","journal-title":"Am. J. Pathol."},{"key":"4508_CR32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/OPX.0000000000000941","volume":"93","author":"OJ Mezu-Ndubuisi","year":"2016","unstructured":"Mezu-Ndubuisi, O. J. In vivo angiography quantifies oxygen-induced retinopathy vascular recovery. Optom. Vis. Sci. 93, 1268\u20131279 (2016).","journal-title":"Optom. Vis. Sci."},{"key":"4508_CR33","first-page":"101","volume":"79","author":"J Ghitman","year":"2017","unstructured":"Ghitman, J., Raluca, S. & Iovu, H. Experimental contributions in the synthesis of Plga nanoparticles with excellent properties for drug delivery: investigation of key parameters. UPB Sci. Bull. B Chem. Mater. Sci. 79, 101\u2013112 (2017).","journal-title":"UPB Sci. Bull. B Chem. Mater. Sci."},{"key":"4508_CR34","doi-asserted-by":"crossref","unstructured":"Eid, M. M. in Handbook of Consumer Nanoproducts 1\u201330 (Springer, 2022).","DOI":"10.1007\/978-981-15-6453-6_89-1"},{"key":"4508_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1159\/000531541","volume":"120","author":"AA Baiad","year":"2023","unstructured":"Baiad, A. A. et al. A meta-analysis of neurodevelopmental outcomes following intravitreal bevacizumab for the treatment of retinopathy of prematurity. Neonatology 120, 577\u2013588 (2023).","journal-title":"Neonatology"},{"key":"4508_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/1735-5362.268207","volume":"14","author":"P Shokoohinia","year":"2019","unstructured":"Shokoohinia, P. et al. Microfluidic-assisted preparation of Plga nanoparticles for drug delivery purposes: experimental study and computational fluid dynamic simulation. Res. Pharm. Sci. 14, 459\u2013470 (2019).","journal-title":"Res. Pharm. Sci."},{"key":"4508_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","volume":"23","author":"T Yasukawa","year":"2004","unstructured":"Yasukawa, T. et al. Drug delivery systems for vitreoretinal diseases. Prog. Retinal Eye Res. 23, 253\u2013281 (2004).","journal-title":"Prog. Retinal Eye Res."},{"key":"4508_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijpharm.2004.12.010","volume":"293","author":"DB Shenoy","year":"2005","unstructured":"Shenoy, D. B. & Amiji, M. M. Poly (Ethylene Oxide)-modified Poly (\u0190-Caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharmaceut. 293, 261\u2013270 (2005).","journal-title":"Int. J. Pharmaceut."},{"key":"4508_CR39","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.ijbiomac.2022.08.063","volume":"221","author":"GDN Atanasio","year":"2022","unstructured":"Atanasio, G. D. N. et al. Bevacizumab encapsulation into Plga nanoparticles functionalized with immunouteroglobin-1 as an innovative delivery system for atherosclerosis. Int. J. Biol. Macromol. 221, 1618\u20131630 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"4508_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119895","volume":"590","author":"M Malakouti-Nejad","year":"2020","unstructured":"Malakouti-Nejad, M. et al. Formulation of nanoliposome-encapsulated bevacizumab (avastin): statistical optimization for enhanced drug encapsulation and properties evaluation. Int. J. Pharmaceut. 590, 119895 (2020).","journal-title":"Int. J. Pharmaceut."},{"key":"4508_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/08982104.2015.1029494","volume":"26","author":"ME Klegerman","year":"2016","unstructured":"Klegerman, M. E. et al. Ultrasound-enhanced bevacizumab release from echogenic liposomes for inhibition of atheroma progression. J. Liposome Res. 26, 47\u201356 (2016).","journal-title":"J. Liposome Res."},{"key":"4508_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41557-021-00752-9","volume":"13","author":"T Bian","year":"2021","unstructured":"Bian, T. et al. Electrostatic Co-assembly of nanoparticles with oppositely charged small molecules into static and dynamic superstructures. Nat. Chem. 13, 940\u2013949 (2021).","journal-title":"Nat. Chem."},{"key":"4508_CR43","doi-asserted-by":"publisher","first-page":"8819","DOI":"10.2147\/IJN.S217038","volume":"14","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Anti-angiogenic activity of bevacizumab-bearing dexamethasone-loaded Plga nanoparticles for potential intravitreal applications. Int. J. Nanomed. 14, 8819\u20138834 (2019).","journal-title":"Int. J. Nanomed."},{"key":"4508_CR44","doi-asserted-by":"crossref","unstructured":"Varshochian, R. et al. The protective effect of albumin on bevacizumab activity and stability in Plga nanoparticles intended for retinal and choroidal neovascularization treatments. Eur. J. Pharmaceut. Sci. 50, 341\u2013352 (2013).","DOI":"10.1016\/j.ejps.2013.07.014"},{"key":"4508_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","volume":"50","author":"R Varshochian","year":"2013","unstructured":"Varshochian, R. et al. The protective effect of albumin on bevacizumab activity and stability in Plga nanoparticles intended for retinal and choroidal neovascularization treatments. Eur. J. Pharm. Sci. 50, 341\u2013352 (2013).","journal-title":"Eur. J. Pharm. Sci."},{"key":"4508_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1517\/14712598.4.1.35","volume":"4","author":"NK Varde","year":"2004","unstructured":"Varde, N. K. & Pack, D. W. Microspheres for controlled release drug delivery. Expert Opin. Biol. Ther. 4, 35\u201351 (2004).","journal-title":"Expert Opin. Biol. Ther."},{"key":"4508_CR47","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.biopha.2018.08.092","volume":"107","author":"X-P Zhang","year":"2018","unstructured":"Zhang, X.-P. et al. Effect of nanoencapsulation using poly (Lactide-Co-Glycolide)(Plga) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. Biomed. Pharmacother. 107, 1056\u20131063 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"4508_CR48","first-page":"653","volume":"8","author":"Z Ye","year":"2015","unstructured":"Ye, Z. et al. Pharmacokinetics and Distributions of Bevacizumab by Intravitreal Injection of Bevacizumab-PLGA Microspheres in Rabbits. Int J. Ophthalmol. 8, 653\u2013658 (2015).","journal-title":"Int J. Ophthalmol."},{"key":"4508_CR49","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","volume":"115","author":"Q Zhu","year":"2008","unstructured":"Zhu, Q. et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-a in patients with choroidal neovascularization. Ophthalmology 115, 1750\u20131755.e1751 (2008).","journal-title":"Ophthalmology"},{"key":"4508_CR50","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU Krohne","year":"2008","unstructured":"Krohne, T. U., Eter, N., Holz, F. G. & Meyer, C. H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. 146, 508\u2013512 (2008).","journal-title":"Am. J. Ophthalmol."},{"key":"4508_CR51","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/ICU.0b013e32835f8ec0","volume":"24","author":"D Johnson","year":"2013","unstructured":"Johnson, D. & Sharma, S. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 24, 205\u2013212 (2013).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"4508_CR52","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow, B. A., Ells, A. L., Gilbert, C. E., Gole, G. A. & Quinn, G. E. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch. Dis. Child Fetal Neonatal Ed. 98, F170\u2013F174 (2013).","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"key":"4508_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.nec.2012.05.002","volume":"23","author":"M Spasic","year":"2012","unstructured":"Spasic, M., Chow, F., Tu, C., Nagasawa, D. T. & Yang, I. Molecular characteristics and pathways of avastin for the treatment of glioblastoma multiforme. Neurosurg. Clin. North Am. 23, 417\u2013427 (2012).","journal-title":"Neurosurg. Clin. North Am."},{"key":"4508_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N., Hillan, K. J. & Novotny, W. Bevacizumab (Avastin), a humanized anti-Vegf monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328\u2013335 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"4508_CR55","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/17425247.2017.1273345","volume":"14","author":"F Sousa","year":"2017","unstructured":"Sousa, F. et al. Nanoparticles for the delivery of therapeutic antibodies: dogma or promising strategy?. Expert Opin. Drug Deliv. 14, 1163\u20131176 (2017).","journal-title":"Expert Opin. Drug Deliv."},{"key":"4508_CR56","doi-asserted-by":"crossref","unstructured":"Alves, A. C. S., Bruinsmann, F. A., Guterres, S. S. & Pohlmann, A. R. Organic nanocarriers for bevacizumab delivery: an overview of development, characterization and applications. Molecules 26, 4127 (2021).","DOI":"10.3390\/molecules26144127"},{"key":"4508_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0b013e318186c64e","volume":"29","author":"R Velez-Montoya","year":"2009","unstructured":"Velez-Montoya, R. et al. The effect of unilateral intravitreal bevacizumab (Avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 29, 20\u201326 (2009).","journal-title":"Retina"},{"key":"4508_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2016.12.025","volume":"176","author":"C Moleta","year":"2017","unstructured":"Moleta, C. et al. Plus disease in retinopathy of prematurity: diagnostic trends in 2016 versus 2007. Am. J. Ophthalmol. 176, 70\u201376 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"4508_CR59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1743-6109.2006.00127.x","volume":"14","author":"S Beckert","year":"2006","unstructured":"Beckert, S. et al. Lactate stimulates endothelial cell migration. Wound Repair Regener. 14, 321\u2013324 (2006).","journal-title":"Wound Repair Regener."},{"key":"4508_CR60","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10456-012-9282-0","volume":"15","author":"PE Porporato","year":"2012","unstructured":"Porporato, P. E. et al. Lactate stimulates angiogenesis and accelerates the healing of superficial and ischemic wounds in mice. Angiogenesis 15, 581\u2013592 (2012).","journal-title":"Angiogenesis"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04508-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:00:08Z","timestamp":1785816008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4508"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04508-w","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}